Dicerna: FDA Clears Application for Treatment of Alcohol Use Disorder

 – Novel ALDH2-Targeting GalXC™ RNAi Candidate Designed to Address a Highly Prevalent and Undertreated Disorder1 –

– Dicerna Expects to Initiate Phase 1 Clinical Trial of DCR-AUD in the Third Quarter of 2021 –

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) ("Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration ("FDA") clearance of its Investigational New Drug (IND) application for DCR-AUD, the Company’s investigational RNAi candidate for the treatment of alcohol use disorder (AUD).

https://finance.yahoo.com/news/dicerna-announces-fda-clearance-investigational-113000232.html